Table A1.

HRs and 95% CIs by Type of OFS Among Eligible Patients

Outcome and Treatment	No. of Patients	HR	95% CI	P
DFS, unadjusted
Tamoxifen v tamoxifen + LHRH analog	228	1.44	0.59 to 3.53	.421
Tamoxifen v tamoxifen + oophorectomy	239	0.93	0.46 to 1.91	.850
Tamoxifen v tamoxifen + radiation	189	1.06	0.32-3.54	.918
DFS, adjusted
Tamoxifen v tamoxifen + LHRH analog	228	1.47	0.59 to 3.65	.408
Tamoxifen v tamoxifen + oophorectomy	239	0.98	0.47 to 2.03	.955
Tamoxifen v tamoxifen + radiation	189	0.93	0.27 to 3.22	.905
OS, unadjusted
Tamoxifen v tamoxifen + LHRH analog	228	1.14	0.37 to 3.49	.822
Tamoxifen v tamoxifen + oophorectomy	239	1.40	0.46 to 4.28	.559
Tamoxifen v tamoxifen + radiation	189	0.57	0.16 to 2.01	.385
OS, adjusted
Tamoxifen v tamoxifen + LHRH analog	228	1.19	0.38 to 3.78	.763
Tamoxifen v tamoxifen + oophorectomy	239	1.38	0.44 to 4.32	.576
Tamoxifen v tamoxifen + radiation	189	0.48	0.12 to 1.82	.277

NOTE. Tamoxifen + ovarian function suppression (OFS) is the reference group for all comparisons. A hazard ratio (HR) > 1 indicates improved outcome for tamoxifen + OFS (ie, higher risk for tamoxifen). Variables included in the adjusted models were age (≤ 40, 41-50, ≥ 51 years), tumor size (< 1, 1-2, > 2 cm), hormone receptor (progesterone receptor (PgR) positive or PgR negative/PgR unknown), and most extensive surgery (breast-sparing procedure or mastectomy). Race and menopausal status were not included because of lack of variability in the data (315 patients were white; 336 patients were premenopausal).

Abbreviations: DFS, disease-free survival; LHRH, luteinizing hormone-releasing hormone; OS, overall survival.